Rosso Rafael, Kalman Jonathan M, Rogowski Ori, Diamant Shmuel, Birger Amir, Biner Simon, Belhassen Bernard, Viskin Sami
Department of Cardiology, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel Aviv University, Israel.
Heart Rhythm. 2007 Sep;4(9):1149-54. doi: 10.1016/j.hrthm.2007.05.017. Epub 2007 May 24.
The mainstay of therapy for catecholaminergic polymorphic ventricular tachycardia (CPVT) is maximal doses of beta-blockers. However, although beta-blockers prevent exercise-induced ventricular tachycardia (VT), most patients continue to have ventricular ectopy during exercise, and some studies report high mortality rates despite beta-blockade.
The purpose of this study was to investigate whether combining a calcium channel blocker with beta-blockers would prevent ventricular arrhythmias during exercise better than beta-blockers alone since the mutations causing CPVT lead to intracellular calcium overload.
Five patients with CPVT and one with polymorphic VT (PVT) and hypertrophic cardiomyopathy who had exercise-induced ventricular ectopy despite beta-blocker therapy were studied. Symptom-limited exercise was first performed during maximal beta-blocker therapy and repeated after addition of oral verapamil.
When comparing exercise during beta-blockers with exercise during beta-blockers + verapamil, exercise-induced arrhythmias were reduced: (1) Three patients had nonsustained VT on beta-blockers, and none of them had VT on combination therapy. (2) The number of ventricular ectopics during the whole exercise test went down from 78 +/- 59 beats to 6 +/- 8 beats; the ratio of ventricular ectopic to sinus beats during the 10-second period recorded at the time of the worst ventricular arrhythmia went down from 0.9 +/- 0.4 to 0.2 +/- 0.2. One patient with recurrent spontaneous VT leading to multiple shocks from her implanted cardioverter-defibrillator (ICD) despite maximal beta-blocker therapy (14 ICD shocks over 6 months while on beta-blockers) has remained free of arrhythmias (for 7 months) since the addition of verapamil therapy.
This preliminary evidence suggests that beta-blockers and calcium blockers could be better than beta-blockers alone for preventing exercise-induced arrhythmias in CPVT.
儿茶酚胺能多形性室性心动过速(CPVT)的主要治疗方法是使用最大剂量的β受体阻滞剂。然而,尽管β受体阻滞剂可预防运动诱发的室性心动过速(VT),但大多数患者在运动期间仍会出现室性早搏,并且一些研究报告称,尽管使用了β受体阻滞剂,死亡率仍很高。
本研究的目的是探讨由于导致CPVT的突变会导致细胞内钙超载,将钙通道阻滞剂与β受体阻滞剂联合使用是否比单独使用β受体阻滞剂能更好地预防运动期间的室性心律失常。
对5例CPVT患者和1例多形性室性心动过速(PVT)合并肥厚型心肌病患者进行了研究,这些患者尽管接受了β受体阻滞剂治疗,但仍有运动诱发的室性早搏。首先在最大剂量β受体阻滞剂治疗期间进行症状限制运动,在加用口服维拉帕米后重复进行。
将β受体阻滞剂治疗期间的运动与β受体阻滞剂+维拉帕米治疗期间的运动进行比较时,运动诱发的心律失常减少:(1)3例患者在使用β受体阻滞剂时有非持续性VT,而在联合治疗时均无VT。(2)整个运动试验期间室性早搏的数量从78±59次降至6±8次;在最严重室性心律失常时记录的10秒期间室性早搏与窦性心律的比率从0.9±0.4降至0.2±0.2。1例尽管接受了最大剂量β受体阻滞剂治疗(在使用β受体阻滞剂期间6个月内发生14次植入式心脏复律除颤器(ICD)电击)仍反复出现自发性VT导致多次ICD电击的患者,自加用维拉帕米治疗后(7个月)一直未发生心律失常。
这一初步证据表明,对于预防CPVT患者运动诱发的心律失常,β受体阻滞剂和钙通道阻滞剂联合使用可能比单独使用β受体阻滞剂更好。